This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PETQ or BLFS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. BLFS: Which Stock Is the Better Value Option?
Should Value Investors Buy These Medical Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
AHCO or PETQ: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. PETQ: Which Stock Is the Better Value Option?
PetIQ (PETQ) Matches Q3 Earnings Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 0.00% and 8.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
PetIQ (PETQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Petco (WOOF) Down 26% This Year So Far: What Should You Do?
by Zacks Equity Research
Petco (WOOF) with its omni-channel distribution and a well-diversified product offering is strongly placed in the pet care industry, which is growing rapidly.
Perrigo (PRGO) Stock Up on Irish Tax Bill Settlement Deal
by Zacks Equity Research
Perrigo (PRGO) agrees to pay an aggregate of approximately $345 million (Euro 297 million) to settle its tax liability notice from the Irish Office of the Revenue Commissioners issued in 2018.
Perrigo (PRGO) to Acquire Another Self-Care Company HRA Pharma
by Zacks Equity Research
Perrigo (PRGO) offers to acquire HRA Pharma with several leading OTC brands in its portfolio for almost $2.1 billion. The acquisition will complete Perrigo's transformation into a leading self-care company.
Hold Petco (WOOF) as It Rides on Continued Demand for Pet Care
by Sapna Bagaria
Petco (WOOF) by dint of its wide product and services portfolio, omni-channel presence and strategic initiatives is well poised to cash in on the expanding petcare industry.
Petco (WOOF) Q2 Earnings Beat on Continued Demand for Pet Care
by Zacks Equity Research
Petco (WOOF) Q2 earnings exceed estimates on buoyant demand for pet care products and services.
New Strong Sell Stocks for August 11th
by Zacks Equity Research
FSLY, LGO, PETQ, VLO, and ICAD have been added to the Zacks Rank #5 (Strong Sell) List on August 11, 2021
PetIQ (PETQ) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of -10.96% and -11.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
PetIQ (PETQ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
NVST vs. PETQ: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. PETQ: Which Stock Is the Better Value Option?
QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance
by Zacks Equity Research
According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.
NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes
by Zacks Equity Research
We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.
Masimo (MASI) Reports Study Findings Backing the SedLine
by Zacks Equity Research
Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.
Medtronic's (MDT) DEFINE AFib Study to Assess AF Burden
by Zacks Equity Research
Medtronic (MDT) begins first app-based study to understand atrial fibrillation burden in patients, utilizing data collected from the LINQ range of insertable cardiac monitors.
Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.
by Zacks Equity Research
Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.
Amedisys' (AMED) Contessa Buyout to Boost Home Health Business
by Zacks Equity Research
Amedisys (AMED) inks deal to acquire Contessa Health to boost home health and hospice services business.
Abbott (ABT) Reports Late-Breaking Data on FreeStyle Libre
by Zacks Equity Research
Late-breaking data on Abbott's (ABT) FreeStyle Libre system demonstrates improvement in health and equity outcomes for diabetes patients.
Charles River (CRL) Advances in Gene Therapy With Vigene Buyout
by Zacks Equity Research
The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.